A 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.
Residents of Indiana now have a National Cancer Institute–designated Comprehensive Cancer Center in their state, and Floridians have another designated Cancer Center in theirs. Both institutions, the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis and the University of Miami Sylvester Comprehensive Cancer Center, are OncLive® Strategic Alliance Partners.
Particularly in the oncology arena, there are several serious scientific, ethical, and pragmatic concerns associated with ongoing reliance on placebo-controlled studies.
My hopes were to be that rare individual who went through life never having to see the sharp end of a Bard-Parker scalpel. That fantasy is about to come to an abrupt end.
A 2018 Giants of Cancer Care award for Community Outreach, Education, and Cancer Policy, Richard L. Schilsky, MD, built a scaffolding upon which new trials were launched into emerging areas of oncology investigation. His work has led to new standards in cancer care, particularly in breast cancer, and along the way he has furthered the careers of many successful and talented oncologists and investigators.
Although there has been significant progress in the field of geriatric oncology, experts say there is still a pressing need to increase clinical trial participation by older patients and to improve the predictive value of assessment tools.
Although concerns have been raised in recent years regarding the need for randomized trials to augment the body of clinical understanding, one critical issue that has failed to generate sufficient discussion is how the choice of the control arm affects the interpretation of an individual study’s outcome and potentially undermines the ethical basis for that particular study.
The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.
A strong unmet need for survivorship care plans exists in the cancer treatment community and better follow-up is required for patients who have moved on from treatment and are experiencing its aftereffects.
Until now, radiation oncology (RO) has remained largely untouched by the valuebased initiatives of the Centers for Medicare and Medicaid Services. The federal agency aims to change that with a proposed RO Model of care that would promote site-neutral payment and take away incentives for volume-based billing.